SCHEMBL20113815

SCHEMBL20113815

CC(C(=O)Nc1ccc(C(F)(F)F)cc1)n1nc(-c2cccc(C(F)(F)F)c2)ccc1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.60
MAPT P10636 6/20 0.52
POLB P06746 4/20 0.49
LMNA P02545 3/20 0.49
TDP1 Q9NUW8 2/20 0.48
THRB P10828 1/20 0.48
FYN P06241 1/20 0.46
HDAC1 Q13547 1/20 0.45
KIF11 P52732 1/20 0.44
TSHR P16473 1/20 0.43
CNR2 P34972 2/20 0.42
MAPK1 P28482 1/20 0.42
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
CNR1 P21554 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20113812 0.91 TP53 (0.57) TP53MAPTPOLBLMNATDP1
SCHEMBL20113814 0.91 TP53 (0.73) TP53MAPTPOLBLMNATDP1
SCHEMBL20113800 0.89 TP53 (0.56) TP53MAPTPOLBLMNATDP1
SCHEMBL20113831 0.89 TP53 (0.56) TP53MAPTPOLBLMNATDP1
SCHEMBL20113811 0.89 TP53 (0.64) TP53MAPTPOLBLMNATDP1
SCHEMBL20113816 0.89 MAPT (0.57) TP53MAPTPOLBLMNATDP1
SCHEMBL20113806 0.88 TP53 (0.59) TP53MAPTPOLBLMNATDP1
SCHEMBL20113803 0.87 TP53 (0.53) TP53MAPTPOLBLMNATDP1
SCHEMBL20114214 0.85 MAPT (0.54) TP53MAPTPOLBLMNAFYN
SCHEMBL20114216 0.84 TP53 (0.59) TP53MAPTPOLBLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
WO-2018081377-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS CFTR, PKD2, CLCN2 TP53 2421/4885MAPT 4874/4885POLB 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.